Yuejun Luo

Clinical significance and inflammatory landscapes of a novel recurrence-associated immune signature in early-stage lung adenocarcinoma

Chaoqi Zhang, Zhen Zhang, Guochao Zhang et al. · Cancer Letters · 2020 · 89 citations

Life Sciences, Immunology, Oncology +17

Comprehensive molecular analyses of a TNF family-based signature with regard to prognosis, immune features, and biomarkers for immunotherapy in lung adenocarcinoma

Chaoqi Zhang, Guochao Zhang, Nan Sun et al. · EBioMedicine · 2020 · 72 citations · Full text

Medicine, Immunology, Oncology +17

m6A regulator expression profile predicts the prognosis, benefit of adjuvant chemotherapy, and response to anti-PD-1 immunotherapy in patients with small-cell lung cancer

Zhihui Zhang, Chaoqi Zhang, Yuejun Luo et al. · BMC Medicine · 2021 · 42 citations · Full text

Medicine, Cancer Biology, Oncology +17

Neoadjuvant chemoradiotherapy versus neoadjuvant chemotherapy for the treatment of esophageal squamous cell carcinoma: a propensity score-matched study from the National Cancer Center in China

Guochao Zhang, Chaoqi Zhang, Nan Sun et al. · Journal of Cancer Research and Clinical Oncology · 2021 · 35 citations · Full text

Medicine, Oncology, Surgery +12

An individualized immune signature of pretreatment biopsies predicts pathological complete response to neoadjuvant chemoradiotherapy and outcomes in patients with esophageal squamous cell carcinoma

Chaoqi Zhang, Guochao Zhang, Nan Sun et al. · Signal Transduction and Targeted Therapy · 2020 · 28 citations · Full text

Medicine, Immunology, Oncology +17